Business, energy, technology, markets and global industry news from Business News Today

head and neck squamous cell carcinoma

PharmaDeviceNews head and neck squamous cell carcinoma
Representative image: A clinical researcher reviews head and neck cancer scans and blood samples as Natera and Aveta Biomics integrate Signatera ctDNA monitoring into the global Phase 3 trial of APG-157.
Pharma & Biotech

Natera and Aveta Biomics bring Signatera into APG-157 Phase 3 head and neck cancer trial

See how Natera’s Signatera could sharpen APG-157’s Phase 3 evidence in head and neck cancer and what risks remain. Read the analysis.

Read More
Representative image of an oncologist reviewing head and neck cancer scans in a modern clinical setting, reflecting Fulgent Genetics’ FID-007 Phase 2 data and the growing search for new post-PD-1 treatment options in recurrent or metastatic head and neck cancer.
Pharma & Biotech

Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026

Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.

Read More
Representative image: Oncology researchers reviewing head and neck cancer imaging data, reflecting the clinical focus of Inhibrx Biosciences’ INBRX-106 HexAgon study update in first-line HNSCC and the broader immuno-oncology race to improve pembrolizumab-based treatment strategies.
Pharma & Biotech

Inhibrx’s HexAgon study may test whether smarter OX40 design can beat old failures

OX40 biology has promised more than it proved. Inhibrx now needs INBRX-106 to show pembrolizumab can work harder in HNSCC.

Read More
Pharma & Biotech

Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?

CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.

Read More